Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Memo Therapeutics

Request full access

An innovator in the field of antibody discovery and immune repertoire analysis

Schlieren, SwitzerlandFounded 2012Biotech & Life Sciences

About Memo Therapeutics

Memo Therapeutics is a biopharmaceutical company specializing in developing innovative treatments for complex diseases through its cutting-edge therapeutic platform. Based on their proprietary technology, Memo Therapeutics focuses on designing highly selective and effective treatments by targeting specific disease mechanisms at the molecular level.

The company's core platform utilizes advanced computational and experimental methods to identify and validate novel therapeutic targets. Memo Therapeutics aims to address unmet medical needs by creating precise and tailored therapies that can improve patient outcomes in challenging areas such as oncology, autoimmune diseases, and neurodegenerative disorders.

Memo Therapeutics' approach combines deep scientific expertise with a commitment to translating discoveries into actionable therapies. Their pipeline includes several promising candidates that are undergoing rigorous preclinical and clinical evaluations. By leveraging state-of-the-art technology and a multidisciplinary team, Memo Therapeutics strives to bring transformative medicines to market, ultimately enhancing the quality of life for patients worldwide.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
45
Open positions
None listed
Dealroom signal
74.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jul 2026 $220M $770M Ipsen ↗
SERIES COther financing May 2024 $18M $115M Ysios Capital · Redalpine · Vesalius Biocapital Partners · Pureos Bioventures ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Memo Therapeutics website traffic

Latest recorded traffic for Memo Therapeutics is 4.5K monthly website visits, up 55.2% over the last three months. Memo Therapeutics's team grew 0% over the past year.

Latest monthly visits4.5K 3-month web change+55.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Memo Therapeutics in the Schlieren ecosystem

Live from Dealroom

The Memo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

  • EVA Basel
  • Redalpine
  • ZKB - Zürcher Kantonalbank
  • Swisscanto Invest
  • Verve Ventures
  • Schroder Adveq
  • Jaquet Partners
  • BERNINA BioInvest
  • Vesalius Biocapital Partners
  • Adjuvant Capital
  • Fresenius Medical Care Ventures
  • GF Group Holding

Series B and later4 investors entered at this stage

  • Schroders Capital
  • Pureos Bioventures
  • Ysios Capital
  • Kurma Partners

Other known investors2 additional known investors

  • ETH Zurich
  • Ipsen
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇨🇭 Switzerland57.9%
🇳🇱 Netherlands15.8%
🇺🇸 United States10.5%
🇩🇪 Germany7.9%
🇪🇸 Spain5.3%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Memo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Memo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.